Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures
Phase of Trial: Phase IV
Latest Information Update: 01 Jan 2012
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms SPIMOS-3D
- 01 Jan 2012 Results published in Bone.
- 27 Jan 2009 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
- 27 Jan 2009 Actual patient numbers (70) added as reported by ClinicalTrials.gov.